CIK 0001746466 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 41.1 M | 36.1 M | 15.8 M | |
| Net income (USD) | -62.4 M | -39.1 M | ||
| Diluted EPS (USD/shares) | -0.39 | -0.38 | -1.85 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-05 | 8-K | 8-K items 8.01 | 2026-10-05 |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-13 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-08-12 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-06-05 | 144 | 144 | |
| 2026-06-05 | 4 | 4 | 2026-06-05 |
| 2026-06-05 | 4 | 4 | 2026-06-04 |
| 2026-06-04 | 144 | 144 | |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 4 | 4 | 2026-05-27 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-29 | 8-K | 8-K items 5.07,9.01 | 2026-05-28 |
| 2026-05-27 | 144 | 144 | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-13 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-13 | 8-K | 8-K items 2.02,9.01 | 2026-05-13 |
| 2026-05-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-16 | EFFECT | EFFECT items ,, | |
| 2026-04-15 | ARS | ARS | 2025-12-31 |
Forms on file (last 1,000): 4 157, 8-K 108, 10-Q 24, 3 18, 144 15, CORRESP 14, UPLOAD 12, 425 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=EQ (0.002 USD), /gw/filings/filings?ticker=EQ&form=8-K, /gw/filings/facts?ticker=EQ&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange